-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 L89Ey8RcW6dI+JoG62N9B1kW7TDVeShzd2lMOWgsNCSf6HLnUIukFk3AQtU3776b
 EY5xnS/fbL6O+aTJBODFug==

<SEC-DOCUMENT>0000012208-03-000007.txt : 20030721
<SEC-HEADER>0000012208-03-000007.hdr.sgml : 20030721
<ACCEPTANCE-DATETIME>20030721164628
ACCESSION NUMBER:		0000012208-03-000007
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20030721
ITEM INFORMATION:		Other events
FILED AS OF DATE:		20030721

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIO RAD LABORATORIES INC
		CENTRAL INDEX KEY:			0000012208
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				941381833
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-07928
		FILM NUMBER:		03794901

	BUSINESS ADDRESS:	
		STREET 1:		1000 ALFRED NOBEL DR
		CITY:			HERCULES
		STATE:			CA
		ZIP:			94547
		BUSINESS PHONE:		5107247000
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>r8kjul21.txt
<TEXT>







                SECURITIES AND EXCHANGE COMMISSION
                     Washington, D.C.  20549





                             FORM 8-K




                          CURRENT REPORT
                Pursuant to Section 13 or 15(d) of
               The Securities Exchange Act of 1934


                  Date of Report:  July 17, 2003
                (Date of earliest event reported)


                    BIO-RAD LABORATORIES, INC.
   ________________________________________________________________
      (exact name of registrant as specified in its charter)


                     Commission File: 1-7928

        Delaware                                94-1381833
   ________________________________________________________________
     (State or other                         (I.R.S. Employer
     jurisdiction of                        Identification No.)
    incorporation or
      organization)



                      1000 Alfred Nobel Drive
                    Hercules, California 94547
   ________________________________________________________________
   (Address of Principal executive offices, including zip code)

                          (510) 724-7000
   ________________________________________________________________
       (Registrant's telephone number, including area code)




   <PAGE>

   ITEM 5.  OTHER EVENTS

        On July 17, 2003, Bio-Rad Laboratories, Inc. issued a press release
   announcing a tender offer for all $88,715,000 aggregate principal amount of
   its outstanding 11 5/8% Senior Subordinated Notes due 2007.  A copy of the
   press release is attached hereto as Exhibit 99.1 and is incorporated herein
   by reference.

        On July 17, 2003, Bio-Rad Laboratories, Inc. also issued a press
   release announcing that it intends to offer, subject to market and other
   conditions, up to $200,000,000 aggregate principal amount of new senior
   subordinated notes in a private offering.  A copy of the press release is
   attached hereto as Exhibit 99.2 and is incorporated herein by reference.



    <PAGE>

   ITEM 7.  FINANCIAL STATEMENT, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS


   (c)  Exhibits

   Exhibit
   Number                            Description

   99.1   Press Release for tender offer of Bio-Rad Laboratories, Inc., dated
          July 17, 2003.
   99.2   Press Release for private offering of Bio-Rad Laboratories, Inc.,
          dated July 17, 2003.

   <PAGE>

                            SIGNATURES



        Pursuant to the requirements of the Securities Exchange Act of 1934,
   the Registrant has duly caused this report to be signed on its behalf by the
   undersigned hereunto duly authorized.


                                      BIO-RAD LABORATORIES, INC.



   Date:  July 21, 2003              By:/s/ Christine A. Tsingos
                                            Christine A. Tsingos
                                            Vice President,
                                            Chief Financial Officer


<PAGE>



                           EXHIBIT INDEX

   Exhibit
   Number                   Description


   99.1   Press Release for tender offer of Bio-Rad Laboratories, Inc., dated
          July 17, 2003.

   99.2   Press Release for private offering of Bio-Rad Laboratories, Inc.,
          dated July 17, 2003.


<PAGE>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>3
<FILENAME>ex991.txt
<DESCRIPTION>99.1
<TEXT>


   EXHIBIT 99.1


   PRESS RELEASE

         Bio-Rad Announces Tender Offer and Consent Solicitation For
              Its 11 5/8% Senior Subordinated Notes Due 2007

   HERCULES, Calif., July 17-- Bio-Rad Laboratories, Inc. (AMEX; BIO; BIO.B),a
   multinational manufacturer and distributor of life science research products
   and clinical diagnostics announced today that on July 17, 2003 it commenced
   a cash tender offer for all $88,715,000 aggregate principal amount of its
   outstanding 11 5/8% Senior Subordinated Notes due 2007 (CUSIP No. 090572AE8).
   In connection with the tender offer, the Company is soliciting holders to
   consent to proposed amendments to the indenture governing the notes, which
   will eliminate substantially all of the restrictive covenants and certain
   related terms.

   The tender offer and consent solicitation will expire at 12:01 a.m., New
   York City time, on Thursday, August 14, 2003, unless extended or terminated
   (including any such extension or termination, the "Expiration Time").
   Holders tendering their notes will be required to consent to the proposed
   amendments. Holders may not tender their notes without delivering consents
   or deliver consents without tendering their notes.

   Tendering holders who validly tender and deliver consents by 5:00 p.m., New
   York City time, on July 30, 2003 (the "Consent Payment Deadline"), will
   receive the total consideration of 110.625% of the principal amount of
   notes, which includes a consent payment of 1.5% of the principal amount of
   the notes.  Holders who validly tender their notes after the Consent Payment
   Deadline and prior to the Expiration Time are not entitled to the consent
   payment, and will receive as payment for their notes the total consideration
   minus the consent payment, or 109.125% of the principal amount of notes. The
   Company expects to make payment on notes validly tendered prior to the
   Consent Payment Deadline promptly following satisfaction of the conditions
   to the offer, and on notes validly tendered after the Consent Payment
   Deadline and prior to the Expiration Time promptly after the Expiration
   Time.  Holders who validly tender their notes will also be paid accrued and
   unpaid interest to, but not including, the applicable date of payment for
   the notes.

   The terms and conditions of the tender offer and consent solicitation,
   including the conditions to the Company's obligation to accept the notes
   tendered and pay the purchase price therefore, are set forth in the
   Company's Offer to Purchase and Consent Solicitation Statement dated
   July 17, 2003. The Company may amend, extend or, subject to certain
   conditions, terminate the tender offer and consent solicitation.

   The Company has retained Goldman, Sachs & Co. to act as the exclusive Dealer
   Manager and Solicitation Agent in connection with the tender offer and
   consent solicitation. Questions regarding the tender offer and consent
   solicitation and requests for documents may be directed to Goldman, Sachs &
   Co. at (800) 828-3182 (toll free) or Bondholder Communications Group, the
   Information Agent in connection with the tender offer and consent
   solicitation, at (888) 385-2663 (toll free).

   This press release shall not constitute an offer or solicitation to purchase
   or a solicitation of consents with respect to any securities. Any such offer
   or solicitation will be made only by means of the Offer to Purchase and
   Consent Solicitation Statement dated July 17, 2003.

   Bio-Rad Laboratories, Inc. is a multinational manufacturer and distributor
   of life science research products and clinical diagnostics.  It is based
   in Hercules, California, and serves more than 70,000 research and industry
   customers worldwide through a network of more than 30 wholly owned
   subsidiary offices.

   Various statements made within this press release may constitute "forward-
   looking statements" for purposes of the Securities and Exchange
   Commission's "safe harbor" provisions under the Private Securities
   Litigation Reform Act of 1995 and Rule 3b-6 under the Securities Exchange
   Act of 1934.  The forward-looking statements contained herein involve risks
   and uncertainties that could cause results to differ materially from the
   Company's expectations.


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>4
<FILENAME>ex992.txt
<DESCRIPTION>99.2
<TEXT>


   EXHIBIT 99.2


   PRESS RELEASE

          Bio-Rad Announces Proposed Private Offering of $200
                  Million of Senior Subordinated Notes

   HERCULES, Calif., July 17, 2003-- Bio-Rad Laboratories, Inc.(AMEX: BIO;
   BIO.B), a multinational manufacturer and distributor of life science
   research products and clinical diagnostics announced today that it intends
   to offer, subject to market and other conditions, up to $200 million
   aggregate principal amount of senior subordinated notes in a private
   offering. The Company intends to use a portion of the net proceeds from this
   offering to fund the purchase of its outstanding 11 5/8% Senior Subordinated
   Notes due 2007 pursuant to the tender offer announced by the Company today.

   The new senior subordinated notes have not been registered under the
   Securities Act of 1933, as amended, or applicable state securities laws, and
   will be offered only to qualified institutional buyers in reliance on Rule
   144A and in offshore transactions pursuant to Regulation S under the
   Securities Act of 1933, as amended. Unless so registered, the new senior
   subordinated notes may not be offered or sold in the United States except
   pursuant to an exemption from the registration requirements of the
   Securities Act and applicable state securities laws.

   This press release shall not constitute an offer to sell or the solicitation
   of an offer to buy these securities, nor shall there be any sale of these
   securities in any state in which such offer, solicitation or sale would be
   unlawful prior to registration or qualification under the securities laws of
   any such state.

   Various statements made within this press release may constitute "forward-
   looking statements" for purposes of the Securities and Exchange
   Commission's "safe harbor" provisions under the Private Securities
   Litigation Reform Act of 1995 and Rule 3b-6 under the Securities Exchange
   Act of 1934. The forward-looking statements contained herein involve risks
   and uncertainties that could cause results to differ materially from the
   Company's expectations.




</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
